Who we are
Axiom Bio is a Gainesville-based biotechnology startup focused on solving one of the most overlooked public health failures: what happens after overdose reversal.
Our first therapy, AXM-101, is a patent-pending, dual-phase injectable designed to not only reverse opioid overdose with naloxone, but also prevent relapse through delayed-release stabilization. We believe the future of overdose care must include both rescue and recovery in one dose.
Founded in 2025, Axiom Bio is committed to creating scalable, life-saving solutions for real-world impact. Our early-stage R&D is based in Florida, with plans to expand into full formulation, clinical partnerships, and translational research in the coming year.
Contact us
Interested in more information?